Ritholtz Wealth Management bought a new stake in shares of SI-Bone Inc (NASDAQ:SIBN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,712 shares of the company’s stock, valued at approximately $254,000.
Several other large investors also recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in shares of SI-Bone by 61.2% during the second quarter. Ameritas Investment Partners Inc. now owns 2,242 shares of the company’s stock valued at $36,000 after buying an additional 851 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of SI-Bone during the second quarter valued at approximately $32,000. Great West Life Assurance Co. Can purchased a new position in shares of SI-Bone during the second quarter valued at approximately $33,000. Two Sigma Advisers LP boosted its position in shares of SI-Bone by 12.3% during the second quarter. Two Sigma Advisers LP now owns 24,700 shares of the company’s stock valued at $394,000 after buying an additional 2,700 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of SI-Bone by 144.6% during the first quarter. BNP Paribas Arbitrage SA now owns 5,779 shares of the company’s stock valued at $69,000 after buying an additional 3,416 shares during the last quarter. 66.66% of the stock is currently owned by institutional investors.
Several research analysts recently issued reports on SIBN shares. Morgan Stanley lifted their target price on SI-Bone from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Zacks Investment Research cut SI-Bone from a “buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Needham & Company LLC boosted their price objective on SI-Bone from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. BidaskClub lowered SI-Bone from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, Canaccord Genuity restated a “buy” rating and issued a $24.00 target price on shares of SI-Bone in a research note on Tuesday, August 4th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $25.14.
SIBN stock traded down $0.63 during trading on Monday, hitting $21.55. 1,044 shares of the company traded hands, compared to its average volume of 231,665. The firm has a market capitalization of $635.01 million, a PE ratio of -12.82 and a beta of 1.37. SI-Bone Inc has a 1 year low of $7.20 and a 1 year high of $26.41. The company has a 50-day moving average of $23.03 and a 200-day moving average of $18.56. The company has a debt-to-equity ratio of 0.36, a quick ratio of 12.75 and a current ratio of 13.18.
SI-Bone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.20. The company had revenue of $14.05 million during the quarter, compared to analysts’ expectations of $9.48 million. SI-Bone had a negative return on equity of 51.27% and a negative net margin of 68.27%. Sell-side analysts expect that SI-Bone Inc will post -1.61 EPS for the current year.
In other SI-Bone news, CFO Laura Francis sold 4,931 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $19.31, for a total transaction of $95,217.61. Following the completion of the transaction, the chief financial officer now owns 143,221 shares of the company’s stock, valued at approximately $2,765,597.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey W. Dunn sold 4,771 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $17.51, for a total value of $83,540.21. The disclosure for this sale can be found here. Insiders have sold a total of 370,886 shares of company stock valued at $8,009,701 over the last 90 days. 15.50% of the stock is currently owned by company insiders.
SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.
Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-Bone Inc (NASDAQ:SIBN).
Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.